ArticleBMC urology2026
Comparative value of postoperative inflammatory indices in predicting recurrence in T3 stage renal cell carcinoma: superiority of the Cally index.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the comparative efficacy of postoperative inflammatory indices (C-reactive protein–Albumin–Lymphocyte Index [Cally Index], Neutrophil-to-Lymphocyte Ratio [NLR], Platelet-to-Lymphocyte Ratio [PLR] and Systemic Inflammation Response Index [SIRI] ) in predicting disease-free survival in patients undergoing radical nephrectomy for T3 stage renal cell carcinoma (RCC).
methodsWe retrospectively analyzed 142 patients who underwent radical nephrectomy for T3 stage RCC between January 2015 and December 2023. Inflammatory indices measured on postoperative days 7–14 were calculated. Optimal cut-off values were determined using ROC curve analysis. Univariate and multivariate Cox regression analyses were performed for disease-free survival assessment.
resultsDuring a median follow-up of 36 months, 33.8% of patients developed recurrence. ROC analysis showed that the Cally Index (Area Under the Curve [AUC]: 0.73) demonstrated superior predictive accuracy compared to SIRI (AUC: 0.69), NLR (AUC: 0.70), and PLR (AUC: 0.66) (p < 0.001). In multivariate analysis, low Cally Index (< 4.5) emerged as the strongest independent prognostic factor (Hazard Ratio [HR]: 2.86, 95% CI: 1.92–4.26, p < 0.001), followed by Fuhrman grade 3–4 (HR: 2.14), SIRI (HR: 1.98), tumor size > 7 cm (HR: 1.82), NLR (HR: 1.76), PLR (HR: 1.65), and lymphovascular invasion (HR: 1.58). Harrell’s C-index values for the Cally Index-based model were significantly higher than other index models.
conclusionPostoperative Cally Index shows superior prognostic value in predicting disease recurrence in T3 stage RCC compared to other inflammatory indices. This finding suggests that an integrated approach evaluating both inflammation and nutritional status may provide clinical benefit in postoperative risk stratification and individualized follow-up strategies.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.